Difference between revisions of "Carboplatin, Pemetrexed, Pembrolizumab in advanced or metastatic non-small cell lung cancer"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "http://www.thelancet.com" to "https://www.thelancet.com")
m (Text replacement - "{| class="wikitable" style="float:right; margin-left: 5px;" |- |back to top |}" to "")
 
(13 intermediate revisions by 2 users not shown)
Line 1: Line 1:
 
<includeonly>Source: [[Carboplatin, Pemetrexed, Pembrolizumab in advanced or metastatic non-small cell lung cancer]]
 
<includeonly>Source: [[Carboplatin, Pemetrexed, Pembrolizumab in advanced or metastatic non-small cell lung cancer]]
−
{| class="wikitable" style="float:right; margin-left: 5px;"
+
</includeonly>
−
|-
 
−
|[[#top|back to top]]
 
−
|}</includeonly>
 
 
<noinclude>
 
<noinclude>
 
{{TOC limit|limit=3}}
 
{{TOC limit|limit=3}}
Line 11: Line 8:
 
</noinclude>
 
</noinclude>
 
===Regimen===
 
===Regimen===
−
{| class="wikitable" style="width: 100%; text-align:center;"
 
−
!Study
 
−
![[Levels_of_Evidence#Evidence|Evidence]]
 
−
|'''[[Overall response rate|ORR]]'''
 
−
!Comparator
 
−
![[Levels_of_Evidence#Efficacy|Efficacy]]
 
−
|-
 
−
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30498-3/fulltext Langer et al. 2016 (KEYNOTE-021)]
 
−
|style="background-color:#1a9851"|Randomized Phase II
 
−
|71%
 
−
|[[#Carboplatin_.26_Pemetrexed|Carboplatin & Pemetrexed]] +/- [[#Pemetrexed_monotherapy_2|pemetrexed maintenance]]
 
−
|style="background-color:#1a9850"|Superior ORR
 
−
|-
 
−
|}
 
−
====Chemoimmunotherapy====
 
−
*[[Carboplatin (Paraplatin)]] AUC 5 IV over 15 to 60 minutes once on day 1 '''given last'''
 
−
*[[Pemetrexed (Alimta)]] 500 mg/m<sup>2</sup> IV over 10 minutes once on day 1 '''given second'''
 
−
*[[Pembrolizumab (Keytruda)]] 200 mg IV over 30 minutes once on day 1, '''given first, at least 30 minutes prior to chemotherapy'''
 
−
 
−
====Supportive medications====
 
−
*"Premedication with [[Folic acid (Folate)|folic acid]], [[Cyanocobalamin (Vitamin B12)|vitamin B12]], and [[:Category:Steroids|corticosteroids]] was administered according to local guidelines."
 
−
 
−
'''21-day cycle for 4 cycles.''' Followed by [[Pembrolizumab & Pemetrexed maintenance therapy for advanced or metastatic non-small cell lung cancer|pembolizumab +/- pemetrexed maintenance therapy]]
 
−
 
−
===References===
 
−
# Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Jalal SI, Panwalkar A, Yang JC, Gubens M, Sequist LV, Awad MM, Fiore J, Ge Y, Raftopoulos H, Gandhi L; KEYNOTE-021 investigators. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016 Nov;17(11):1497-1508 [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30498-3/fulltext link to original article] '''contains verified protocol''' [http://thelancet.com/cms/attachment/2074509559/2069027402/mmc1.pdf supplementary appendix]; [https://www.ncbi.nlm.nih.gov/pubmed/27745820 PubMed]
 

Latest revision as of 11:19, 26 July 2022



Regimen in use at


Regimen

Retrieved from "https://hemonc.org/w/index.php?title=Carboplatin,_Pemetrexed,_Pembrolizumab_in_advanced_or_metastatic_non-small_cell_lung_cancer&oldid=57770"